Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1977 1
2006 1
2007 1
2008 3
2009 2
2010 1
2011 6
2012 4
2013 1
2014 4
2015 6
2016 8
2017 7
2018 4
2019 7
2020 7
2021 7
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, Fakih MG, Gholami S, Hong TS, Jaiyesimi I, Klute K, Lieu C, Sanoff H, Strickler JH, White S, Willis JA, Eng C. Morris VK, et al. J Clin Oncol. 2023 Jan 20;41(3):678-700. doi: 10.1200/JCO.22.01690. Epub 2022 Oct 17. J Clin Oncol. 2023. PMID: 36252154 Free PMC article.
METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Five systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria. ...
METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical pr …
Nattokinase atherothrombotic prevention study: A randomized controlled trial.
Hodis HN, Mack WJ, Meiselman HJ, Kalra V, Liebman H, Hwang-Levine J, Dustin L, Kono N, Mert M, Wenby RB, Huesca E, Rochanda L, Li Y, Yan M, St John JA, Whitfield L. Hodis HN, et al. Clin Hemorheol Microcirc. 2021;78(4):339-353. doi: 10.3233/CH-211147. Clin Hemorheol Microcirc. 2021. PMID: 33843667 Clinical Trial.
OBJECTIVE: To determine the effect of nattokinase on subclinical atherosclerosis progression and atherothrombotic biomarkers. METHODS: In this double-blinded trial, 265 individuals of median age 65.3 years, without clinical evidence of cardiovascular disease (CVD) w …
OBJECTIVE: To determine the effect of nattokinase on subclinical atherosclerosis progression and atherothrombotic biomarkers. METHODS: In th …
Epidemiology of esophageal cancer: update in global trends, etiology and risk factors.
Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V. Uhlenhopp DJ, et al. Clin J Gastroenterol. 2020 Dec;13(6):1010-1021. doi: 10.1007/s12328-020-01237-x. Epub 2020 Sep 23. Clin J Gastroenterol. 2020. PMID: 32965635 Review.
Guidelines for esophageal adenocarcinoma are more well established but lack concrete evidence in the form of randomized controlled trials. This review will discuss the epidemiology, risk factors, and current prevention strategies for esophageal cancer in depth. ...
Guidelines for esophageal adenocarcinoma are more well established but lack concrete evidence in the form of randomized controlled trials …
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition).
Cossarizza A, Chang HD, Radbruch A, Acs A, Adam D, Adam-Klages S, Agace WW, Aghaeepour N, Akdis M, Allez M, Almeida LN, Alvisi G, Anderson G, Andrä I, Annunziato F, Anselmo A, Bacher P, Baldari CT, Bari S, Barnaba V, Barros-Martins J, Battistini L, Bauer W, Baumgart S, Baumgarth N, Baumjohann D, Baying B, Bebawy M, Becher B, Beisker W, Benes V, Beyaert R, Blanco A, Boardman DA, Bogdan C, Borger JG, Borsellino G, Boulais PE, Bradford JA, Brenner D, Brinkman RR, Brooks AES, Busch DH, Büscher M, Bushnell TP, Calzetti F, Cameron G, Cammarata I, Cao X, Cardell SL, Casola S, Cassatella MA, Cavani A, Celada A, Chatenoud L, Chattopadhyay PK, Chow S, Christakou E, Čičin-Šain L, Clerici M, Colombo FS, Cook L, Cooke A, Cooper AM, Corbett AJ, Cosma A, Cosmi L, Coulie PG, Cumano A, Cvetkovic L, Dang VD, Dang-Heine C, Davey MS, Davies D, De Biasi S, Del Zotto G, Dela Cruz GV, Delacher M, Della Bella S, Dellabona P, Deniz G, Dessing M, Di Santo JP, Diefenbach A, Dieli F, Dolf A, Dörner T, Dress RJ, Dudziak D, Dustin M, Dutertre CA, Ebner F, Eckle SBG, Edinger M, Eede P, Ehrhardt GRA, Eich M, Engel P, Engelhardt B, Erdei A, Esser C, Everts B, Evrard M, Falk CS, Fehniger TA, Felipo-Benavent M, Fer… See abstract for full author list ➔ Cossarizza A, et al. Eur J Immunol. 2019 Oct;49(10):1457-1973. doi: 10.1002/eji.201970107. Eur J Immunol. 2019. PMID: 31633216 Free PMC article.
The Long and Short of Tamoxifen Therapy: A Review of the ATLAS Trial.
Smith GL. Smith GL. J Adv Pract Oncol. 2014 Jan;5(1):57-60. J Adv Pract Oncol. 2014. PMID: 25032035 Free PMC article. Review.
Review of "Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial" by Davies et al. (2013), Lancet, 381, 805-816. For another perspective on the ATLAS …
Review of "Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-p …
Laparoscopic Gastric Bypass.
Seeras K, Philip K, Baldwin D, Prakash S. Seeras K, et al. 2023 Sep 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Sep 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30085510 Free Books & Documents.
The first case series of laparoscopic Roux-en-Y gastric bypass (RYGB) was presented in 1994 by Drs. Wittgrove and Clark, and the largest trial was reported by Nguyen and colleagues in 2001. Much data has proven that the laparoscopic approach to RYGB results in decreases in …
The first case series of laparoscopic Roux-en-Y gastric bypass (RYGB) was presented in 1994 by Drs. Wittgrove and Clark, and the largest …
LAT1 enables T cell activation under inflammatory conditions.
Ogbechi J, Wright HL, Balint S, Topping LM, Kristina Z, Huang YS, Pantazi E, Swart M, Windell D, Marin E, Wempe MF, Endou H, Thomas AM, Filer A, Stone TW, Clarke AJ, Dustin ML, Williams RO. Ogbechi J, et al. J Autoimmun. 2023 Jul;138:103031. doi: 10.1016/j.jaut.2023.103031. Epub 2023 May 23. J Autoimmun. 2023. PMID: 37229811
Finally, it was shown that a small molecule LAT1 inhibitor, currently undergoing clinical trials in man, was highly effective in treating experimental arthritis in mice. ...
Finally, it was shown that a small molecule LAT1 inhibitor, currently undergoing clinical trials in man, was highly effective …
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.
Sahai V, Griffith KA, Beg MS, Shaib WL, Mahalingam D, Zhen DB, Deming DA, Zalupski MM. Sahai V, et al. Cancer. 2022 Oct 1;128(19):3523-3530. doi: 10.1002/cncr.34394. Epub 2022 Jul 27. Cancer. 2022. PMID: 35895381 Free PMC article. Clinical Trial.
The addition of an anti-programmed death receptor (PD-1)/PD-ligand (L1) antibody to either systemic chemotherapy or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody has shown benefit in multiple solid tumors. METHODS: In this phase 2 trial, patients 18 yea …
The addition of an anti-programmed death receptor (PD-1)/PD-ligand (L1) antibody to either systemic chemotherapy or anti-cytotoxic T-lymphoc …
Lessons from a large-scale COVID-19 vaccine trial.
Mahla RS, Dustin LB. Mahla RS, et al. J Clin Invest. 2022 Sep 15;132(18):e163202. doi: 10.1172/JCI163202. J Clin Invest. 2022. PMID: 36106630 Free PMC article.
Safety, efficacy, and durability of immune protection are the key parameters of randomized controlled trials (RCTs) and are essential for vaccine approvals, global distribution, and comprehensive population-vaccination programs. ...They report that protection lasted throug …
Safety, efficacy, and durability of immune protection are the key parameters of randomized controlled trials (RCTs) and are essential …
Current Status of Transcatheter Tricuspid Valve Therapies.
Romeo JD, Bashline MJ, Fowler JA, Kliner DE, Toma C, Smith AC, Sultan I, Sanon S. Romeo JD, et al. Heart Int. 2022 Jun 16;16(1):49-58. doi: 10.17925/HI.2022.16.1.49. eCollection 2022. Heart Int. 2022. PMID: 36275351 Free PMC article. Review.
Given the rapid development of many tricuspid systems and multiple on-going clinical trials, the aim of this review is to highlight the current state of transcatheter tricuspid therapeutics and to provide an up-to-date view of their clinical use, outcomes and …
Given the rapid development of many tricuspid systems and multiple on-going clinical trials, the aim of this review is to high …
76 results